LENZ vs. KYMR, APGE, TWST, CGON, SRRK, SWTX, VCEL, BEAM, TARS, and RXRX
Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Kymera Therapeutics (KYMR), Apogee Therapeutics (APGE), Twist Bioscience (TWST), CG Oncology (CGON), Scholar Rock (SRRK), SpringWorks Therapeutics (SWTX), Vericel (VCEL), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "biological products, except diagnostic" industry.
LENZ Therapeutics vs.
Kymera Therapeutics (NASDAQ:KYMR) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.
LENZ Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics.
54.3% of LENZ Therapeutics shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 38.4% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Kymera Therapeutics had 6 more articles in the media than LENZ Therapeutics. MarketBeat recorded 14 mentions for Kymera Therapeutics and 8 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.58 beat Kymera Therapeutics' score of 0.33 indicating that LENZ Therapeutics is being referred to more favorably in the news media.
Kymera Therapeutics received 40 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 51.58% of users gave Kymera Therapeutics an outperform vote.
Kymera Therapeutics presently has a consensus price target of $49.15, suggesting a potential upside of 5.78%. LENZ Therapeutics has a consensus price target of $35.40, suggesting a potential upside of 26.75%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Kymera Therapeutics.
LENZ Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -178.27%. Kymera Therapeutics' return on equity of -28.88% beat LENZ Therapeutics' return on equity.
Kymera Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Summary
LENZ Therapeutics beats Kymera Therapeutics on 8 of the 15 factors compared between the two stocks.
Get LENZ Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LENZ Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LENZ) was last updated on 11/2/2024 by MarketBeat.com Staff
